Odonate Therapeutics LLC to Post FY2017 Earnings of ($1.83) Per Share, Jefferies Group Forecasts (ODT)

Odonate Therapeutics LLC (NASDAQ:ODT) – Equities researchers at Jefferies Group issued their FY2017 earnings estimates for Odonate Therapeutics in a research note issued to investors on Tuesday. Jefferies Group analyst M. Yee expects that the company will post earnings of ($1.83) per share for the year. Jefferies Group has a “Buy” rating and a $40.00 price target on the stock. Jefferies Group also issued estimates for Odonate Therapeutics’ Q4 2017 earnings at ($0.46) EPS, Q1 2018 earnings at ($0.56) EPS, Q2 2018 earnings at ($0.69) EPS, Q3 2018 earnings at ($0.83) EPS, Q4 2018 earnings at ($0.96) EPS, FY2018 earnings at ($3.03) EPS and FY2019 earnings at ($3.21) EPS.

Several other brokerages also recently issued reports on ODT. Goldman Sachs Group initiated coverage on shares of Odonate Therapeutics in a report on Tuesday. They set a “neutral” rating and a $27.00 price target for the company. Cowen initiated coverage on shares of Odonate Therapeutics in a research note on Tuesday. They issued an “outperform” rating for the company.

Odonate Therapeutics (ODT) opened at $24.13 on Thursday. Odonate Therapeutics has a 1-year low of $22.31 and a 1-year high of $25.36.

In other Odonate Therapeutics news, CEO Kevin C. Tang acquired 1,291,666 shares of the business’s stock in a transaction dated Thursday, December 7th. The shares were acquired at an average price of $24.00 per share, with a total value of $30,999,984.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Boxer Capital, Llc acquired 416,666 shares of the business’s stock in a transaction dated Wednesday, December 6th. The stock was acquired at an average cost of $24.00 per share, for a total transaction of $9,999,984.00. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 1,709,332 shares of company stock valued at $41,023,268.

ILLEGAL ACTIVITY WARNING: “Odonate Therapeutics LLC to Post FY2017 Earnings of ($1.83) Per Share, Jefferies Group Forecasts (ODT)” was posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this story can be viewed at https://www.chaffeybreeze.com/2018/01/04/odonate-therapeutics-llc-to-post-fy2017-earnings-of-1-83-per-share-jefferies-group-forecasts-odt.html.

Odonate Therapeutics Company Profile

Odonate Therapeutics, LLC is a pharmaceutical company. The Company is engaged in the development of therapeutics to improve and extend the lives of patients with cancer. It is focused on the development of tesetaxel, a novel chemotherapy agent. It has completed Phase-II studies in patients with metastatic breast cancer (MBC).

Receive News & Ratings for Odonate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odonate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply